1. Home
  2. DCOY vs DUKRW Comparison

DCOY vs DUKRW Comparison

Compare DCOY & DUKRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DCOY

Decoy Therapeutics Inc. Common Stock

N/A

Current Price

$6.11

Market Cap

4.2M

Sector

Health Care

ML Signal

N/A

DUKRW

DUKE Robotics Corp. Warrant

N/A

Current Price

$1.00

Market Cap

4.3M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
DCOY
DUKRW
Founded
N/A
N/A
Country
United States
Israel
Employees
11
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Aerospace
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
4.2M
4.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DCOY
DUKRW
Price
$6.11
$1.00
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$30.00
N/A
AVG Volume (30 Days)
240.7K
12.9K
Earning Date
05-16-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.70
52 Week High
$13.51
$1.43

Technical Indicators

Market Signals
Indicator
DCOY
DUKRW
Relative Strength Index (RSI) 44.91 28.29
Support Level $5.08 $0.70
Resistance Level $6.47 $1.29
Average True Range (ATR) 1.25 0.12
MACD -0.11 -0.02
Stochastic Oscillator 2.99 41.10

Price Performance

Historical Comparison
DCOY
DUKRW

About DCOY Decoy Therapeutics Inc. Common Stock

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

Share on Social Networks: